glycolate oxidase

Glycolate oxidase-IN-1 (compound 26), a salicylic acid derivative, serves as an inhibitor of glycolate oxidase (GO) and exhibits an inhibitory concentration (IC50) of 38.2 μM. It is efficacious in reducing oxalate production in hyperoxaluric hepatocytes and has potential applications in researching primary hyperoxaluria type 1 (PH1) [1].

Glycolic acid oxidase inhibitor 1 (compound 2 in table 1) is an inhibitor of glycolate oxidase, which reduces the risk of kidney stone formation. It also inhibits the contraction of guinea pig ileum induced by slow reactive substances (SRS-A) caused by allergic reactions, and has therapeutic potential for the treatment of allergic diseases such as asthma.

3-Phenyllactic acid (PhLA) is a broad spectrum antimicrobial compound active against bacteria and fungi, DL-3-Phenyllactic acid (3-Phenyllactic acid) is a reagent involved in biological studies of nantioselectivity of lipase in transesterification and oxidation by glycolate oxidase and catalase.

Vamagloxistat (sodium) functions as an inhibitor of glycolate oxidase, and is designed to treat hyperoxaluria and kidney stones.

5-(2-Furyl)-2-hydroxybenzoic acid is an inhibitor of glycolate oxidase (GO) and can be used to study metabolism-related disorders such as primary hyperoxaluria type 1 (PH1).

LDHA-IN-5 is a novel and potent inhibitor targeting both glycolate oxidase (GO) and lactate dehydrogenase A (LDHA), designed for the treatment of primary hyperoxaluria.

Vamagloxistat is a glycolate oxidase inhibitor utilized to mitigate hyperoxaluria and reduce the formation of kidney stones [1].